Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia
Key facts
- Who runs it
- UNC Lineberger Comprehensive Cancer Center
- Where
- Chapel Hill, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- 8 Aug 2025
- Expected to end
- Jan 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- standard radiotherapy
- experimental radiotherapy
- Record updated
- 5 September 2025
- Why it stopped
- Operational reason
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Written informed consent was obtained to participate in the study and HIPAA authorization for the release of personal health information
- Subjects is willing and able to comply with study procedures based on the judgment of the investigator
- Age ≥ 18 years at the time of consent
- T0-4, N0-3, M0 disease American Joint Committee on Cancer (AJCC 7th or 8th edition) of the oropharynx (this includes patients with head and neck cancer of unknown primary origin, often categorized as T0 disease, who will be treated with radiotherapy to the oropharynx) planned for definitive radiotherapy +/- chemotherapy; 5 No contraindications to receiving MRI such as implanted electrical devices, pregnancy, and significant quantities of metal in the head/neck
Who cannot take part
- Prior history of radiation therapy to the head and neck
- Patients with Sjogren's syndrome or baseline xerostomia (CTCAE > 0 for the question regarding dry mouth)
- Patients with an allergy to lemon juice
- Patients with lesions grossly involving the salivary glands
Other criteria
- In order to participate in this study a subject must meet all of the eligibility criteria outlined below. Eligibility must be maintained up for the subject to be considered eligible for treatment
Where in United States
- University of North Carolina at Chapel Hill, Department of Radiation OncologyChapel Hill, United States
About the trial
What the trial wants to find out
Radiation-induced xerostomia (dry mouth) is one of the most common and severe toxicities experienced by patients undergoing radiation treatment for head and neck cancer. Radiation-induced dry mouth is a frequently experienced symptom and persists after treatment, potentially indefinitely. Current practice does not specifically attempt to spare the parotid ducts, where stem/progenitor cells are believed to preferentially reside, and considers the entire salivary gland to have equal function. New radiation therapy planning and conducting strategies are needed to reduce this toxicity and maximize patient quality of life post-treatment.
Read full original descriptionShow less
This randomized Phase II study explores the contribution of magnetic resonance imaging (MRI) guided salivary gland duct definition to decrease patient-reported xerostomia in patients with oropharynx cancer receiving radiation therapy. The severity of xerostomia will be measured by patient-reported (PRO) symptoms, saliva secretion, saliva pH, and buffering.
The 2 groups in the trial
- Mean ParotidExisting treatment, for comparison
Standard radiotherapy planning aims to restrict the mean parotid radiation dose to less than or equal to 14 Gy.
Treatment: standard radiotherapy
- Parotid DuctTreatment being tested
Magnetic resonance images will be used to localize the parotid ducts and limit the radiation dose to these structures to less than or equal to 14 Gy.
Treatment: experimental radiotherapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Assessment of Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia Following Radiotherapy for Oropharynx Cancer
- Record updated
- 5 September 2025